CN106580994A - Enrofloxacin hydrochloride composition and liquid medicine, and preparation methods thereof - Google Patents
Enrofloxacin hydrochloride composition and liquid medicine, and preparation methods thereof Download PDFInfo
- Publication number
- CN106580994A CN106580994A CN201611169901.9A CN201611169901A CN106580994A CN 106580994 A CN106580994 A CN 106580994A CN 201611169901 A CN201611169901 A CN 201611169901A CN 106580994 A CN106580994 A CN 106580994A
- Authority
- CN
- China
- Prior art keywords
- silkworm
- enrofloxacin
- septicaemia
- enrofloxacin hcl
- medicinal liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PZJWYUDBXNNVLZ-UHFFFAOYSA-N 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid;hydrochloride Chemical compound Cl.C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 PZJWYUDBXNNVLZ-UHFFFAOYSA-N 0.000 title claims abstract description 117
- 239000007788 liquid Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title abstract description 77
- 241000255789 Bombyx mori Species 0.000 claims abstract description 165
- 206010040047 Sepsis Diseases 0.000 claims abstract description 103
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 11
- 241000894006 Bacteria Species 0.000 claims description 91
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 29
- 239000008101 lactose Substances 0.000 claims description 26
- 239000002671 adjuvant Substances 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000000575 pesticide Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 3
- 150000002772 monosaccharides Chemical group 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 208000013223 septicemia Diseases 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 20
- PGNYNCTUBKSHHL-UHFFFAOYSA-N 2,3-diaminobutanedioic acid Chemical compound OC(=O)C(N)C(N)C(O)=O PGNYNCTUBKSHHL-UHFFFAOYSA-N 0.000 abstract description 8
- 235000008708 Morus alba Nutrition 0.000 abstract description 3
- 240000000249 Morus alba Species 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 32
- 229940079593 drug Drugs 0.000 description 29
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 25
- 230000001681 protective effect Effects 0.000 description 25
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 23
- 229960000740 enrofloxacin Drugs 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 16
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 14
- 230000000844 anti-bacterial effect Effects 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 229960003405 ciprofloxacin Drugs 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000000857 drug effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 244000052616 bacterial pathogen Species 0.000 description 7
- 229960003276 erythromycin Drugs 0.000 description 7
- 238000011835 investigation Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 239000000273 veterinary drug Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000021060 food property Nutrition 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 241000255791 Bombyx Species 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- JLDCNMJPBBKAHH-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide Chemical compound [Na+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 JLDCNMJPBBKAHH-UHFFFAOYSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229960001182 sulfadiazine sodium Drugs 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NMOJAXCSURVGEY-UHFFFAOYSA-N N#CC#N.[S] Chemical compound N#CC#N.[S] NMOJAXCSURVGEY-UHFFFAOYSA-N 0.000 description 1
- IQBDNAFWMWZTMD-UHFFFAOYSA-N N#CO.[S] Chemical compound N#CO.[S] IQBDNAFWMWZTMD-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940088515 ciloxan Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- -1 on the one hand Chemical compound 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an enrofloxacin hydrochloride composition and a liquid medicine, and preparation methods thereof, and relates to the field of application of enrofloxacin hydrochloride. The composition comprises, by mass, 2.5-10% of enrofloxacin hydrochloride and 90-97.5% of a water-soluble pharmaceutic adjuvant. Added is added to the enrofloxacin hydrochloride composition to prepare the liquid medicine, and the concentration of the enrofloxacin hydrochloride in the liquid medicine is 250-1000 mg/L; and the liquid medicine is sprinkled on mulberry leaves to obtain medicinal leaves, and the medicinal leaves are used to feed bombyx mori in order to control black chest septicaemia and serratial septicemia of the bombyx mori. The liquid medicine can simultaneously control the black chest septicaemia and serratial septicemia of the bombyx mori, has a better bombyx mori black chest septicaemia control effect than a traditional medicine erythromycin thiocyanate, and has an obvious bombyx mori serratial septicemia control effect than a traditional medicine enrofloxacin hydrochloride.
Description
Technical field
The present invention relates to the application of Enrofloxacin HCL, and in particular to a kind of Enrofloxacin HCL compositionss, medicinal liquid
And preparation method.
Background technology
Silkworm industry occupies critical role in national economy.Affect current China's Silk Industry overall economic benefit it is many because
In element, silkworm evil of being critically ill is one of principal element.According to incompletely statistics, China current silkworm disease loss rate is 15% or so, by current
China produces 440000 tons of cocoon meter per year, every year because silkworm disease damage loses up to 60,000 tons or so of Bombyx bombycis, is worth more than 800,000,000 yuan, and because silkworm is critically ill evil
Cause silk quality low, the loss caused to whole industry is just more difficult to estimate.
In common silkworm disease, bacterial diseases are long-term existence and endanger one of serious disease, and its loss rate accounts for silkworm disease loss rate
More than 20%, due to the seriousness of its liability, complexity and harm, the effective preventing and treating to bacterial diseases, be always silkworm
The emphasis of sick prevention and control research field.Septicaemia and clever bacterium septicemia are all common silkworm diseases, in addition to the ovum phase, larva, pupa,
3 stages of development of moth can occur, and summer autumn silkworm rearing season is more universal.Black breast deteriorated blood bacterium, clever bacterium and blue or green head deteriorated blood bacterium are the masters of primary disease
Want pathogenetic bacteria.In the market, the common drug for treating silkworm septicaemia is sulfur hydracid erythromycin, treats silkworm spirit bacterium
Septicemia common drug is ciprofloxacin, on the one hand, sulfur hydracid erythromycin and ciprofloxacin are to the black breast deteriorated blood of silkworm
Disease and the septicemic cemia therapeutic effect of clever bacterium are not fine, and when concentration is 200mg/L, therapeutic effect only reaches 85.59%, improves and uses
Concentration easily causes the side effect such as Drug resistance, and with the increase of service life, its prevention effect can be gradually lowered；The opposing party
Face, as silkworm Jing often suffers from silkworm septicaemia and clever bacterium septicemia simultaneously, and do not have on market can and meanwhile prevent and
Two kinds of sick medicines for the treatment of.
The content of the invention
The invention aims to overcome the shortcomings of above-mentioned background technology, there is provided a kind of Enrofloxacin HCL compositionss,
Medicinal liquid and preparation method, the present invention can prevent and treat septicaemia and clever bacterium septicemia simultaneously, and, the present invention is to black
The septicemic cemia prevention effect of breast is substantially better than conventional medicament sulfur hydracid erythromycin, and the septicemic cemia prevention effect of clever bacterium is substantially better than
Conventional medicament ciprofloxacin.
The present invention provides a kind of for preventing and treating silkworm septicaemia and the septicemic cemia Enrofloxacin HCL compositionss of clever bacterium,
By percentage to the quality, said composition is used by 2.5%～10% Enrofloxacin HCL and 90%～97.5% water-soluble pesticide
Adjuvant is constituted.
On the basis of above-mentioned technical proposal, by percentage to the quality, the compositionss by 5% Enrofloxacin HCL and
95% water solublity pharmaceutic adjuvant composition.
On the basis of above-mentioned technical proposal, the water solublity pharmaceutic adjuvant is monosaccharide or soluble polysaccharide.
On the basis of above-mentioned technical proposal, the water solublity pharmaceutic adjuvant is Lactose, glucose, in soluble starch
Any one.
The present invention provides the preparation method of above-mentioned Enrofloxacin HCL compositionss, comprises the following steps：
By percentage to the quality, the water-soluble pesticide of 2.5%～10% Enrofloxacin HCL and 90%～97.5% is used
Adjuvant is mixed, and obtains Enrofloxacin HCL compositionss.
The present invention provides a kind of for preventing and treating silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, it is characterised in that：Should
Medicinal liquid is made using the Enrofloxacin HCL compositionss as any one of Claims 1-4, hydrochloric acid grace promise in the medicinal liquid
The concentration of Sha Xing is 250～1000mg/L.
On the basis of above-mentioned technical proposal, the concentration of the middle Enrofloxacin HCL is 500mg/L.
The present invention provides the above-mentioned preparation method for preventing and treating silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, including
Following steps：
A certain amount of Enrofloxacin HCL compositionss are taken, is added water and is configured to medicinal liquid, hydrochloric acid En Nuosha in the medicinal liquid
The concentration of star is 250～1000mg/L.
On the basis of above-mentioned technical proposal, in the medicinal liquid, the concentration of Enrofloxacin HCL is 500mg/L.
Compared with prior art, advantages of the present invention is as follows：
(1) compositionss that the present invention is provided can play prevention simultaneously to silkworm septicaemia and clever bacterium septicemia and control
Therapeutic effect, it is simple, efficient, practical, wrong medicine is not resulted in, so as to delay treatment, causes Bombyx bombycis to lose, to reducing silkworm disease damage
Lose significant.
(2) present invention is substantially better than conventional medicament to silkworm septicaemia and the septicemic cemia prevention and treatment effect of clever bacterium
Sulfur hydracid erythromycin and ciprofloxacin, can further reduce silkworm disease loss rate, improve cocoon yield and quality.Jing drug effects
Test proves that Enrofloxacin HCL is respectively 99.67% He to silkworm septicaemia and the septicemic cemia effective percentage of clever bacterium
99.50%, total effective rate is 99.17%, respectively higher than the effective percentage of erythromycin thiocyanate, ciprofloxacin, and there is pole
Significant difference.
Specific embodiment
With reference to specific embodiment, the present invention is described in further detail.
The embodiment of the present invention provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia Enrofloxacin HCL combination of clever bacterium
Thing, by percentage to the quality, said composition by 2.5%～10% Enrofloxacin HCL and 90%～97.5% water-soluble pesticide
Constituted with adjuvant.Preferably, said composition is made up of 5% Enrofloxacin HCL and 95% water solublity pharmaceutic adjuvant.It is water-soluble
Property pharmaceutic adjuvant can be monosaccharide or soluble polysaccharide, for example, can be Lactose, glucose, any in soluble starch
One kind, as Lactose can improve taking food property of the silkworm to medicine leaf, and lactose stabilized is preferably, is difficult the moisture absorption, therefore, it is water-soluble
Property pharmaceutic adjuvant is preferably Lactose.
The preparation method of above-mentioned Enrofloxacin HCL compositionss is：By percentage to the quality, by 2.5%～10% hydrochloric acid
Enrofloxacin and 90%～97.5% water solublity pharmaceutic adjuvant are mixed, and obtain Enrofloxacin HCL compositionss.
The embodiment of the present invention also provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, and the medicinal liquid contains
The concentration of Enrofloxacin HCL is 250～1000mg/L, preferably 500mg/L.Its preparation method is：Take a certain amount of above-mentioned salt
Sour enrofloxacin compositionss, add water and are configured to medicinal liquid, and in the medicinal liquid, the concentration of Enrofloxacin HCL is 250～1000mg/L,
Preferably 500mg/L；
The using method of the medicinal liquid is：By medicine liquid spray on Folium Mori, medicine leaf is obtained, using medicine leaf feeding silkworm, be used for
Silkworm septicaemia and clever bacterium septicemia are prevented and treated simultaneously.Wherein, the detailed process using medicine leaf feeding silkworm is as follows：In health
The 3rd day, first day of the 5th age and the 3rd day of the 4th age of silkworm larva, each feeding medicine leaf of upper cluster the previous day once, feed every time
The time of food is 6h；When finding to have silkworm infection septicemia pathogenic bacterium, find infected silkworm first day to whole silkworms
Continuous feeding medicine leaf three times, the time of each feeding is 8h, and once, the time of each feeding is 6h to daily feeding medicine leaf later.
Below by 7 specific embodiments, the present invention is described in detail.
Embodiment 1：
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia Enrofloxacin HCL compositionss of clever bacterium, with
Mass percent meter, said composition are mixed by 5% Enrofloxacin HCL and 95% Lactose.
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, and its preparation method is：Take
5g Enrofloxacin HCL compositionss (hydrochloric enrofloxacin 250mg) are dissolved in 500ml water, obtain prevent and treat silkworm septicaemia and
The septicemic cemia medicinal liquid of clever bacterium, in medicinal liquid, Enrofloxacin HCL concentration is 500mg/L.
Embodiment 2：
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia Enrofloxacin HCL compositionss of clever bacterium, with
Mass percent meter, said composition are mixed by 5% Enrofloxacin HCL and 95% Lactose.
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, and its preparation method is：Take
5g Enrofloxacin HCL compositionss (hydrochloric enrofloxacin 250mg) are dissolved in 1000ml water, obtain preventing and treating silkworm septicaemia
With the septicemic cemia medicinal liquid of clever bacterium, in medicinal liquid, Enrofloxacin HCL concentration is 250mg/L.
Embodiment 3：
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia Enrofloxacin HCL compositionss of clever bacterium, with
Mass percent meter, said composition are mixed by 5% Enrofloxacin HCL and 95% Lactose.
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, and its preparation method is：Take
5g Enrofloxacin HCL compositionss (hydrochloric enrofloxacin 250mg) are dissolved in 250ml water, obtain prevent and treat silkworm septicaemia and
The septicemic cemia medicinal liquid of clever bacterium, in medicinal liquid, Enrofloxacin HCL concentration is 1000mg/L.
Embodiment 4：
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia Enrofloxacin HCL compositionss of clever bacterium, with
Mass percent meter, said composition are mixed by 2.5% Enrofloxacin HCL and 97.5% Lactose.
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, and its preparation method is：Take
5g Enrofloxacin HCL compositionss (hydrochloric enrofloxacin 250mg) are dissolved in 500ml water, obtain prevent and treat silkworm septicaemia and
The septicemic cemia medicinal liquid of clever bacterium, in medicinal liquid, Enrofloxacin HCL concentration is 500mg/L.
Embodiment 5：
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia Enrofloxacin HCL compositionss of clever bacterium, with
Mass percent meter, said composition are mixed by 10% Enrofloxacin HCL and 90% Lactose.
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, and its preparation method is：Take
5g Enrofloxacin HCL compositionss (hydrochloric enrofloxacin 250mg) are dissolved in 500ml water, obtain prevent and treat silkworm septicaemia and
The septicemic cemia medicinal liquid of clever bacterium, in medicinal liquid, Enrofloxacin HCL concentration is 500mg/L.
Embodiment 6：
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia Enrofloxacin HCL compositionss of clever bacterium, with
Mass percent meter, said composition are mixed by 5% Enrofloxacin HCL and 95% glucose.
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, and its preparation method is：Take
5g Enrofloxacin HCL compositionss (hydrochloric enrofloxacin 250mg) are dissolved in 500ml water, obtain prevent and treat silkworm septicaemia and
The septicemic cemia medicinal liquid of clever bacterium, in medicinal liquid, Enrofloxacin HCL concentration is 500mg/L.
Embodiment 7：
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia Enrofloxacin HCL compositionss of clever bacterium, with
Mass percent meter, said composition are mixed by 10% Enrofloxacin HCL and 90% soluble starch.
The present embodiment provides a kind of preventing and treating silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, and its preparation method is：Take
5g Enrofloxacin HCL compositionss (hydrochloric enrofloxacin 250mg) are dissolved in 500ml water, obtain prevent and treat silkworm septicaemia and
The septicemic cemia medicinal liquid of clever bacterium, in medicinal liquid, Enrofloxacin HCL concentration is 500mg/L.
The principle of the present invention is explained with 5 tests below.
Test 1：Drug screening test
The common antibacterials in market are chosen as reagent is supplied, silkworm septicaemia and the pathogenic thalline of clever bacterium septicemia is carried out
Outer bacteriostatic test.Bacteria suspension is made using 20ml aseptic water washing lawns by every antibacterial inclined-plane to experimental study, it is double-deck
Method is down flat plate, and lower floor's blank meat soup (MH) culture medium adds 1% (V/V) bacteria suspension, in every Oxford cup in the MH culture medium of upper strata
200 μ l are added for the solution (drug level is 50mg/L) of reagent thing.37 DEG C of overnight incubations, it is transparent aseptic around measurement Oxford cup
Loop diameter size, per group of test are parallel three times, and record data is averaged, statistical analysiss antibacterial effect respectively for reagent thing
Really.As shown in table 1.1：
Table 1.1, for reagent thing inhibition zone test result (diameter：mm)
Shown according to 1.1 interpretation of result of table, black breast deteriorated blood bacterium antibacterial circle diameter is with enrofloxacin maximum (25.27mm), high
In control erythromycin thiocyanate (20.72mm)；Clever bacterium deteriorated blood bacterium antibacterial circle diameter is maximum with compound sulfadiazine sodium
(30.29mm), higher than control ciprofloxacin (25.91mm), but all it is effectively hydrochloric acid grace to two kinds of bacterium fungistatic effects
Promise sand star, its antibacterial circle diameter is 24.94mm and 28.22mm, is above control drug, also, Enrofloxacin HCL is water-soluble
Property medicine, meet silkworm antibacterials requirement.
Test 2：Adjuvant screening test
These three adjuvant dissolubilities of Lactose, glucose, soluble starch and color and luster meet soluble powder formulation requirements, but
Glucose powder and the easy moisture absorption of soluble starch, Lactose are difficult the moisture absorption, stability preferably, accordingly, it is determined that Lactose be this preparation most
Good compatibility adjuvant.
Comparative study is carried out to the proportioning of Enrofloxacin HCL and Lactose, Enrofloxacin HCL is carried out in proportion with Lactose
Dispensing, is then made into the medicinal liquid of the 500mg/L in terms of Enrofloxacin HCL, in the ratio sprinkling Mulberry of 500ml medicine liquid spray 5kg Folium Mori
Leaf, then Folium Mori are raised into silkworm, as a result as shown in table 2.1.
The proportioning result of table 2.1, Enrofloxacin HCL and Lactose
From table 2.1 as can be seen that Lactose can improve taking food property of the silkworm to medicine leaf, Enrofloxacin HCL is more beneficial for
Absorb and utilize.Lactose content more than 95%, can promote to eat Mulberry 10%, therefore select lactose content >=95%, in order to ensure medicine
Effect, proportioning are preferably Enrofloxacin HCL 5%, Lactose 95%.
Test 3：Enrofloxacin HCL dose screening is tested
To the silkworm inoculating strain of health so that silkworm infected silkworm septicaemia and clever bacterium septicemia, by sense
The Folium Mori of variable concentrations trial drug and control drug, and then relative analyses trial drug and control were sprayed in the silkworm feed of dye
Therapeutic effect of the medicine to silkworm, and then filter out suitable drug level.
Test organismss are inoculated on nutrient agar slant medium and cultivate 24h, during test, by 2ml aseptic water washing lawns
Bacteria suspension is made, black breast deteriorated blood bacterium dilutes 10 times, and clever bacterium dilutes 100 times.Dipped with the Inoculating needle of Jing alcohol burner flame sterilizations few
Amount bacterium solution is to percutaneous puncture-inoculation under silkworm body surface from 5 ages.Start medicine feed leaf after terminating from inoculation, 24 hours whole medicine feeds in the 1st day
Leaf, the 2nd, 3 days difference medicine feed leaves 6 hours.Silkworm is grouped and Folium Mori classification is referring to table 3.1.
Table 3.1, the test of Enrofloxacin HCL dose screening
Investigated according to the symptom that test silkworm morbidity is dead.I.e.：Septicaemia silkworm has just stubbornly refused long chest blackening, after rear
Expand to whole body；After death whole body is rubescent soon for clever bacterium septicemia.Death rate of the onset in positive controls investigation statisticses 72 hours,
It is dead that administration treatment group continues raising investigation morbidity in 48 hours in addition to the Affected individuals number during investigation administration, after the administration is complete
Die silkworm number, add up to total morbidity number, be calculated as follows protective rate.Test is repeated 3 times, statistical average protective rate.
Drug effect judgment basis Ministry of Agriculture veterinary drug evaluation center《Veterinary drug investigative technique guideline collects (2006-2011)》
Regulation in page 131～132 " silkworm antimicrobial drug evaluating drug effect experimental technique guideline ", carries out drug effect judgement.Tool
Body is：Positive controls death rate of the onset >=95.0%, judges the antimicrobial drug with average protective rate >=90.0% of medicine group
Thing treatment is effective.
Using infected silkworm of the feeding without medicine Folium Mori as positive control, to be uninfected by silkworm as negative control, test knot
Fruit and analysis are referring to table 3.2：
The prevention effect of table 3.2, Enrofloxacin HCL compositionss to silkworm septicaemia
Table 3.3, Enrofloxacin HCL compositionss are to the septicemic cemia prevention effect of silkworm spirit bacterium
Referring to shown in table 3.2～3.3, bacterium is septicemic cemia prevents and treats result to silkworm septicaemia and spirit for Enrofloxacin HCL
Show, 500, the prevention effect of concentration 2 kinds of bacteremic septicemias above-mentioned to silkworm of 1000mg/L more than 90%, 125,
The prevention effect of the concentration of 250mg/L 2 kinds of bacteremic septicemias above-mentioned to silkworm is below 90%, and test repeatability is good.
Test 4：Therapeutic effect is tested
To the silkworm inoculating strain of health so that silkworm infects septicaemia and clever bacterium septicemia, by sense simultaneously
The silkworm feed sprinkling overtesting medicine and the Folium Mori of control drug of dye, and then relative analyses trial drug and control drug are to family
The therapeutic effect of silkworm.Detailed process is as follows：
Test organismss are inoculated on nutrient agar slant medium and cultivate 24h, during test, by 2ml aseptic water washing lawns
Bacteria suspension is made, black breast deteriorated blood bacterium dilutes 10 times, and clever bacterium dilutes 100 times.Dipped with the Inoculating needle of Jing alcohol burner flame sterilizations few
Amount bacterium solution is to percutaneous puncture-inoculation under silkworm body surface from 5 ages.Start medicine feed leaf after terminating from inoculation, 24 hours whole medicine feeds in the 1st day
Leaf, the 2nd, 3 days difference medicine feed leaves 6 hours.Require according to silkworm pharmacodynamic study, silkworm is grouped and Folium Mori classification such as 4.1 institute of table
Show.
Table 4.1, test silkworm grouped table
Medication is referred to《Veterinary drug national standard collects》First (compiling within 2010 at Ministry of Agriculture's veterinary drug evaluation center) page 64
Enrofloxacin solution (silkworm use).Take respectively Enrofloxacin HCL compositionss 10g (hydrochloric enrofloxacin 0.5g) be dissolved in 2000,
1000th, 500ml water, be made into concentration be 250,500, the medicinal liquid of 1000mg/L, take each 500ml of above-mentioned medicinal liquid and spray Folium Mori 5kg；Take sulfur
Cyanic acid erythromycin (silkworm use) 1 (50mg), is dissolved in 500ml water, takes Ciloxan (silkworm use) (2ml:50mg)5
, 500ml water is dissolved in, above-mentioned 2 kinds of solution 500ml are taken respectively, each spray Folium Mori 5kg during sprinkling with Folium Mori tow sides moistening is
Degree.Design from inoculation by test group and after terminating, start medicine feed leaf, the 1st day, feed medicine leaf 24 hours, difference feed on the the 2nd and the 3rd
Medicine leaf 6 hours, remaining time feed common Folium Mori.
Investigated according to the symptom that test silkworm morbidity is dead.I.e.：Septicaemia silkworm has just stubbornly refused long chest blackening, after rear
Expand to whole body；After death whole body is rubescent soon for clever bacterium septicemia.Death rate of the onset in positive controls investigation statisticses 72 hours,
It is dead that administration treatment group continues raising investigation morbidity in 48 hours in addition to the Affected individuals number during investigation administration, after the administration is complete
Die silkworm number, add up to total morbidity number, be calculated as follows protective rate.Test is repeated 3 times, statistical average protective rate.
Drug effect judgment basis Ministry of Agriculture veterinary drug evaluation center《Veterinary drug investigative technique guideline collects (2006-2011)》
Regulation in page 131～132 " silkworm antimicrobial drug evaluating drug effect experimental technique guideline ", carries out drug effect judgement.Tool
Body is：Positive controls death rate of the onset >=95.0%, judges the antimicrobial drug with average protective rate >=90.0% of medicine group
Thing treatment is effective.
Enrofloxacin HCL compositionss are to the therapeutic effect and significance difference analysis of silkworm septicaemia referring to table 4.2
And shown in table 4.3：
The therapeutic effect of table 4.2, Enrofloxacin HCL compositionss to silkworm septicaemia
Table 4.3, Enrofloxacin HCL compositionss are to silkworm septicaemia protective rate significance difference analysis
From table 4.2 and table 4.3, positive control death rate of the onset ＞ 95%, 500mg/L, 1000mg/L group are averagely protected
Shield rate is more than 90%, and compares higher than erythromycin thiocyanate.Protective rate analysis result shows, 250mg/L, 500mg/L,
There is pole significant difference between 1000mg/L concentration group and the control of sulfur hydracid erythromycin.
Enrofloxacin HCL compositionss the silkworm septicemic cemia therapeutic effect of spirit bacterium and significance difference analysis are shown in Table 4.4 and
Table 4.5.
Table 4.4, Enrofloxacin HCL compositionss are to the septicemic cemia prevention effect of silkworm spirit bacterium
Table 4.5, Enrofloxacin HCL compositionss are to silkworm spirit bacterium septicemia protective rate significance difference analysis
Referring to shown in table 4.4 and table 4.5, Enrofloxacin HCL compositionss are to the septicemic cemia clinical test results of silkworm spirit bacterium
Show, positive control death rate of the onset ＞ 95%, the average protective rate of 500mg/L, 1000mg/L group is more than 90%, and is higher than sulfur cyanogen
Sour erythromycin control.Protective rate analysis result shows, is not significantly different between 500mg/L and 1000mg/L concentration groups, they
There is pole significant difference to 250mg/L concentration groups, there were significant differences to ciprofloxacin group for 500mg/L concentration group, does not extremely show
Difference is write, 1000mg/L concentration group has pole significant difference to ciprofloxacin control.
Enrofloxacin HCL 500mg/L trial zones to the protective rate of silkworm septicaemia up to 92.56%, to clever bacterium deteriorated blood
The protective rate of disease is above control drug, is the least concentration of protective rate ＞ 90% 91.94%.Therefore, Enrofloxacin HCL
Recommended dose be set to 500mg/L.
Test 5：Experiment of preventive effects
Test silkworm is raised under normal conditions, natural occurrence.By to silkworm feed sprinkling overtesting medicine and control
The Folium Mori of medicine, and then the preventive effect of relative analyses trial drug and control drug to silkworm.
Drug effect checkout procedure adopts 3 test groups and 1 matched group：Enrofloxacin HCL compositionss test group uses medicament
(counting with Enrofloxacin HCL) is measured as 500mg/L, silkworm septicaemia clinical trial matched group medicine erythromycin thiocyanate group
Dosage be 100mg/L, the dosage of silkworm spirit bacterium septicemia clinical trial control drug ciprofloxacin group is
500mg/L, matched group are clear water matched group.Repeat 3rd area, per 200, area silkworm.
Investigational agent 500ml water is taken, Folium Mori 5kg is sprayed, is added food to silkworm.The 3rd day the 4th age of healthy silkworm larva, the 5th
First day age and the 3rd day, each medicine feed leaf of upper cluster the previous day once, each feeding time 6h；When sick silkworm is found, first day even
Continuous adding eats three times, per 8h once, once a day later, each feeding time 6h.
Investigated according to the dead symptom of test silkworm morbidity before feeding leaf every morning, i.e.,：Septicaemia is just stubbornly refused by silkworm
Chest blackening, expands to whole body after long；After death whole body is rubescent soon for clever bacterium septicemia, and the morbidity for recording above-mentioned 2 kinds of silkworms disease is dead
Die number, for the silkworm of above-mentioned disease carries out the isolation identification of pathogenic bacterium, confirm as could counting for correspondence pathogenic bacterium.Control time
Start to being only placed on small straw bundles to spin cocoons for four-aged silkworm.Death rate of the onset and protective rate are investigated before being placed on small straw bundles to spin cocoons.
It is calculated as follows protective rate.Test is repeated 3 times, statistical average protective rate.
Table 5.1, septicaemia silkworm pathogenic bacterium isolation identification result
Table 5.2, clever bacterium septicemia silkworm pathogenic bacterium isolation identification result
Table 5.3, various medicines are to the septicemic cemia protective rate of silkworm
Table 5.4, various medicines are to silkworm septicaemia protective rate significance difference analysis
Table 5.5, various medicines are to silkworm spirit bacterium septicemia protective rate significance difference analysis
Various medicines are calculated in table 5.3 to the septicemic cemia protective rate result of silkworm according to the data of table 5.1～5.2.
Referring to shown in table 5.3, with Enrofloxacin HCL to the septicemic cemia protective rate highest of silkworm, which is to the average protective rate of septicaemia
For 99.67%, be 99.50% to the average protective rate of clever bacterium septicemia, total protective rate is 99.17%, higher than erythromycin thiocyanate,
Ciprofloxacin and clear water control.Referring to shown in table 5.4～5.5, significance difference analysis show that Enrofloxacin HCL group is protected
Shield rate shows significant difference and pole significant difference to other all matched groups.
Silkworm to be tested is placed on small straw bundles to spin cocoons after harvesting of cocoon and carries out Bombyx bombycis economic characters investigation, that is, investigate amount of cocoon crop, cocoon weight, cocoon shell weight, cocoon
Layer rate, dead cage rate, investigate impact of the medicine to Bombyx bombycis economic characters.
Table 5.6, Cocoon Quality Traits is investigated
Table 5.7, cocoon weight significance difference analysis
Table 5.8, cocoon shell weight significance difference analysis
Table 5.9, Cocoon layer ratio significance difference analysis
Referring to shown in 5.6～table of table 5.9, the survey showed that for Cocoon Quality Traits, and Enrofloxacin HCL is in cocoon weight, cocoon layer
Compare with each drug control and clear water in terms of amount, Cocoon layer ratio and there is no significant difference.
The principle of the present invention is described below：
, used as model insects, its metabolic studies is clearly, complete with aquatic animal, birds, mammal for silkworm
It is complete different.In silkworm itself and silkworm body, the sensitivity of Pathogens is also entirely different, and silkworm is just meaned once falling ill
Death, prevention silkworm disease is the most important thing.
At present, existing correlational study proves that enrofloxacin compositionss can be used in treating bacterial silkworm septicemia,
Patent No. CN102000092A discloses the compositionss that a kind of sulfadiazine sodium is formed with enrofloxacin, trimethoprim, is used for
Bacterial silkworm septicemia is treated in prevention.Wherein, enrofloxacin is water insoluble, need to be made into during use turbid liquid spraying in
Silkworm is fed on Folium Mori, affects taking food property of the silkworm to medicine leaf, enrofloxacin to be difficult to be absorbed and used into after silkworm body, and in the short time
Interior enteral road is excreted with feces, as a result causes enrofloxacin not high in silkworm body absorption rate and blood drug concentration, its point
Sub- state is also unfavorable for which plays antibacterial effect, thus to preventing or treating bacterial silkworm septicemia effect on driving birds is not good.Need
Compositionss are formed with other drugs, be can be only achieved while preventing and treating the effect of silkworm septicaemia bacterium and clever bacterium deteriorated blood pathogenic bacteria
Really.
Enrofloxacin HCL is used to prevent or treat bacterial silkworm septicemia and have no to have been reported that.Enrofloxacin HCL
It is similar with enrofloxacin antibacterial effect, but physicochemical property is entirely different, and its using method and use range are also different.Therefore, grind
Enrofloxacin HCL is studied carefully while to septicaemia bacterium and the antibacterial effect and using dosage of clever bacterium deteriorated blood pathogenic bacteria, to silkworm antibacterial
Property septicemia prevention and treatment it is most important.
The present invention provides a kind of Enrofloxacin HCL compositionss, medicinal liquid and preparation method, with Enrofloxacin HCL as activity
Composition, mass content are 5%, add adjuvant Lactose, and mass content is 95%.The Main Function of Lactose is filler, is not affected
The stability and curative effect of crude drug, while during administration soluble in water, can adhere on unique food Folium Mori of silkworm, and promote
Silkworm is taken food to Enrofloxacin HCL medicine leaf.The present invention provides a kind of new application of Enrofloxacin HCL, specifically refers to hydrochloric acid
Enrofloxacin prevents and treats silkworm septicaemia and the purposes in clever bacterium septicemia medicine at the same time.Enrofloxacin HCL one
As be used for bacterial other Animal diseases for the treatment of, use it for preventing and treating silkworm septicaemia and clever bacterium deteriorated blood
Disease is had no precedent in prior art.In prior art, the conventional medicine of silkworm septicaemia and clever bacterium septicemia is treated
Respectively erythromycin thiocyanate and ciprofloxacin, and Enrofloxacin HCL has to silkworm septicaemia and clever bacterium septicemia
Effect is prevented and treated preferably.According to above-mentioned purposes, Enrofloxacin HCL compositionss, medicinal liquid and preparation method are being applied
When, it is configured to the aqueous solution that hydrochloric enrofloxacin concentration is 500mg/L.
Present invention research finds that absorbance is higher after Enrofloxacin HCL enters bombyx mori intestinal, soluble in water due to which, enters
Exist in ionic condition after entering silkworm body, blood drug concentration is persistently raised, eliminate relatively slow after reaching peak value, when can remain longer
Between fungistatic effect.In the present invention, adjuvant Lactose can improve taking food property of the silkworm to medicine leaf, be more beneficial for Enrofloxacin HCL
Absorption and utilization.
The compositionss that the present invention is provided have preferable effect to preventing and treating silkworm septicaemia and clever bacterium septicemia,
Enrofloxacin HCL and Lactose are taken, aqueous solution is made into according to mass content, wherein hydrochloric enrofloxacin 500mg/L, Lactose
9500mg/L, is sprayed on Folium Mori and feeds silkworm, and the Jing tests of pesticide effectiveness are proved, Enrofloxacin HCL is lost to silkworm septicaemia and clever bacterium
The effective percentage of disorders of blood is respectively 99.67% and 99.50%, and total effective rate is 99.17%, higher than erythromycin thiocyanate, hydrochloric acid ring
Third husky star control, and there is pole significant difference.
Why the Enrofloxacin HCL compositionss of the present invention, medicinal liquid and preparation method are to silkworm septicaemia and clever bacterium
Septicemia has preferable curative effect, is because the third generation carbostyril family antibacterial drugs that Enrofloxacin HCL is synthesis, also known as ethyl
Ciprofloxacin, enrofloxacin.On October 4th, 1996 obtains FDA approvals, is poultry and the special carbostyril family antibacterial drugs of Aquatic product.I
State was registered as novel chiral synthon in 2010, had been widely used in veterinary clinic.With broad spectrum antibiotic activity, with very strong infiltration
Property, oral absorption is good, and blood drug level is high and stable, and its metabolite is Ciprofloxacin, still has powerful antibacterial action.Medicine is direct
The nucleus of antibacterial are acted on, is suppressed DNA of bacteria gyrase, is caused antibacterial quick death, be not likely to produce drug resistance.It is anti-with other
Rhzomorph is without cross resistance.In addition, Enrofloxacin HCL and adjuvant do not affect taking food property of the silkworm to unique food Folium Mori.
As Folium Mori are entered after bombyx mori intestinal, can excrete at short notice, Enrofloxacin HCL can be quickly absorbed into by silkworm
Silkworm body simultaneously plays a role.
Those skilled in the art can carry out various modifications and variations to the embodiment of the present invention, if these modifications and change
Within the scope of the claims in the present invention and its equivalent technologies, then these modifications and modification are also in protection scope of the present invention for type
Within.
The prior art that the content not described in detail in description is known to the skilled person.
Claims (9)
- It is 1. a kind of to be used to prevent and treat silkworm septicaemia and the septicemic cemia Enrofloxacin HCL compositionss of clever bacterium, it is characterised in that： By percentage to the quality, said composition is used by 2.5%～10% Enrofloxacin HCL and 90%～97.5% water-soluble pesticide Adjuvant is constituted.
- 2. it is as claimed in claim 1 to be used to prevent and treat silkworm septicaemia and the septicemic cemia Enrofloxacin HCL combination of clever bacterium Thing, it is characterised in that：By percentage to the quality, the compositionss are used by 5% Enrofloxacin HCL and 95% water-soluble pesticide Adjuvant is constituted.
- 3. it is as claimed in claim 1 to be used to prevent and treat silkworm septicaemia and the septicemic cemia Enrofloxacin HCL combination of clever bacterium Thing, it is characterised in that：The water solublity pharmaceutic adjuvant is monosaccharide or soluble polysaccharide.
- 4. it is as claimed in claim 3 to be used to prevent and treat silkworm septicaemia and the septicemic cemia Enrofloxacin HCL combination of clever bacterium Thing, it is characterised in that：The water solublity pharmaceutic adjuvant is Lactose, glucose, any one in soluble starch.
- 5. the preparation method of Enrofloxacin HCL compositionss as claimed in claim 1, it is characterised in that comprise the following steps：By percentage to the quality, by 2.5%～10% Enrofloxacin HCL and 90%～97.5% water solublity pharmaceutic adjuvant Mixed, obtained Enrofloxacin HCL compositionss.
- It is 6. a kind of to be used to prevent and treat silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, it is characterised in that：The medicinal liquid is using as weighed Profit requires that the Enrofloxacin HCL compositionss any one of 1 to 4 are made, and in the medicinal liquid, the concentration of Enrofloxacin HCL is 250～1000mg/L.
- It is 7. as claimed in claim 6 to be used to prevent and treat silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, it is characterised in that：Institute The concentration for stating middle Enrofloxacin HCL is 500mg/L.
- 8. it is used for as claimed in claim 6 preventing and treating the preparation method of silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, its It is characterised by, comprises the following steps：A certain amount of Enrofloxacin HCL compositionss are taken, is added water and is configured to medicinal liquid, Enrofloxacin HCL in the medicinal liquid Concentration is 250～1000mg/L.
- 9. it is used for as claimed in claim 8 preventing and treating the preparation method of silkworm septicaemia and the septicemic cemia medicinal liquid of clever bacterium, its It is characterised by：In the medicinal liquid, the concentration of Enrofloxacin HCL is 500mg/L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611169901.9A CN106580994A (en) | 2016-12-16 | 2016-12-16 | Enrofloxacin hydrochloride composition and liquid medicine, and preparation methods thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611169901.9A CN106580994A (en) | 2016-12-16 | 2016-12-16 | Enrofloxacin hydrochloride composition and liquid medicine, and preparation methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106580994A true CN106580994A (en) | 2017-04-26 |
Family
ID=58601010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611169901.9A Pending CN106580994A (en) | 2016-12-16 | 2016-12-16 | Enrofloxacin hydrochloride composition and liquid medicine, and preparation methods thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106580994A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737567A (en) * | 2022-10-19 | 2023-03-07 | 湖南中科汇智信息服务有限公司 | Enrofloxacin soluble powder capable of reducing bitter taste and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1600311A (en) * | 2003-09-26 | 2005-03-30 | 周元铎 | Medication in silkworm use for treating bacteriosis and preparation method |
| CN102000092A (en) * | 2010-12-10 | 2011-04-06 | 湖北农科生物化学有限公司 | New application of sulfadiazine sodium |
-
2016
- 2016-12-16 CN CN201611169901.9A patent/CN106580994A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1600311A (en) * | 2003-09-26 | 2005-03-30 | 周元铎 | Medication in silkworm use for treating bacteriosis and preparation method |
| CN102000092A (en) * | 2010-12-10 | 2011-04-06 | 湖北农科生物化学有限公司 | New application of sulfadiazine sodium |
Non-Patent Citations (2)
| Title |
|---|
| 张安启等: "防治家蚕细菌病药物的筛选", 《山东畜牧兽医》 * |
| 王彦文等: "《省力高效生产实用新技术》", 31 August 2014, 中国农业科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737567A (en) * | 2022-10-19 | 2023-03-07 | 湖南中科汇智信息服务有限公司 | Enrofloxacin soluble powder capable of reducing bitter taste and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107308117A (en) | A kind of Tilmicosin pre-mixing agent and preparation method thereof | |
| CN109999027B (en) | Use of melatonin | |
| CN102697787A (en) | Application of ponazuril to prevention and treatment of coccidiosis | |
| CN106580994A (en) | Enrofloxacin hydrochloride composition and liquid medicine, and preparation methods thereof | |
| CN102000092B (en) | New application of sulfadiazine sodium in preparing medicine for preventing or treating Bombyx mori septicemia | |
| CN106620668A (en) | Compound tilmicosin solid dispersing agent and preparation method thereof | |
| CN115192642B (en) | Preparation method and application of composite biological preparation with parasiticidal function and containing Brevibacillus laterosporus and fermented traditional Chinese medicine | |
| CN110179756A (en) | A kind of tilmicosin micro-capsule preparation and preparation method thereof | |
| CN103918935B (en) | A kind of pet food additives | |
| CN104474526A (en) | Pharmaceutical composition for treating or/and preventing pet viral diseases and preparation method thereof | |
| CN103524448A (en) | Enrofloxacin-saccharin compound | |
| CN101829129B (en) | Veterinary compound gentamycin sulfate injection and preparation method thereof | |
| CN106554385B (en) | Polypeptide compound and application thereof in livestock and poultry | |
| CN101199520A (en) | Beta-Lacetam anti-biotic compound dose for animal containing benemid | |
| CN106539754A (en) | Hydrobromic acid antifebrile dichroanone solution and preparation method thereof | |
| CN103222975A (en) | Application of enrofloxacin salt in preparation of swine oral preparation | |
| CN106727300A (en) | A kind of thiabendazolum supensoid agent and preparation method thereof | |
| CN102813909A (en) | Compound doxycycline hydrochloride composition for preventing and treating colibacillosis and chronic respiratory disease of poultry as well as preparation method thereof | |
| CN102805772A (en) | Application of coptis chinensis, amur cork-tree bark, Chinese rhubarb and skullcap dysentery inhibiting particles to preparation of medicines for treating intestinal diseases of poultry, and medicinal composition formed by compounding particles | |
| CN102973584B (en) | Composition for treating nematodosis in dogs and cats, and preparation method thereof | |
| CN112826797A (en) | Novel compound anti-coccidium soluble powder and preparation method thereof | |
| CN105617353A (en) | Oral administration composition of colistin | |
| CN109364089A (en) | It is a kind of with the composition and preparation method thereof for killing helminth effect | |
| US11981645B1 (en) | N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound | |
| CN107737338A (en) | A kind of preparation for improving sensibility of bacteria on antibiotic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |